NCT00330915

A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.

A Feasibility Study of Pemetrexed Single Agent and Folic Acid Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to help answer the following research questions: If the study drug Pemetrexed can help patients with rectal cancer; If molecular biological parameters are correlated respectively changing due to cytotoxic treatment with Pemetrexed; To evaluate adverse events

Conditions

• Rectal Neoplasms

Interventions

Type	Name	Description
DRUG	pemetrexed	500 mg/m2, intravenous (IV), every 21 days x 3 cycles

Timeline

• Start date: 2006-06-01
• Primary completion: 2008-06-01
• Completion: 2008-06-01
• First posted: 2006-05-29
• Last updated: 2009-07-21
• Results posted: 2009-07-21

Locations

1 site across 1 country: Sweden